Q-omics provides the consensus-scored ACTBP8 profile across patient tissues and cancer cell-line models. ACTBP8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ACTBP8 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, ACTBP8 RNA expression shows 12,541 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, HNSC, and TGCT as cancer lineages where ACTBP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTBP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTBP8 survival associations across molecular data types. ACTBP8 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTBP8 RNA expression–survival associations across cancer types. High ACTBP8 expression shows unfavorable associations in STAD, MESO, ACC, OV and THCA, but favorable associations in CESC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for ACTBP8 RNA expression.
This table summarizes ACTBP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ACTBP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTBP8 shows higher tumor expression in HNSC, COAD, LIHC, THCA, BRCA and LUAD. The HNSC box plot shows higher ACTBP8 RNA expression in tumor versus normal tissue (log2 FC = +0.225, t-test p = .005).
This table shows molecular features associated with ACTBP8 in patient tissues and cancer cell lines. In patient samples, ACTBP8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
